Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)

• Published in: Journal of affective disorders 2022-12, Vol.319, p.646-654
• Main Authors: Martinotti, Giovanni, Vita, Antonio, Fagiolini, Andrea, Maina, Giuseppe, Bertolino, Alessandro, Dell'Osso, Bernardo, Siracusano, Alberto, Clerici, Massimo, Bellomo, Antonello, Sani, Gabriele, d'Andrea, Giacomo, Chiaie, Roberto Delle, Conca, Andreas, Barlati, Stefano, Di Lorenzo, Giorgio, De Fazio, Pasquale, De Filippis, Sergio, Nicolò, Giuseppe, Rosso, Gianluca, Valchera, Alessandro, Nucifora, Domenica, Di Mauro, Stefania, Bassetti, Roberta, Martiadis, Vassilis, Olivola, Miriam, Belletti, Sandro, Andriola, Ileana, Di Nicola, Marco, Pettorruso, Mauro, McIntyre, Roger S., di Giannantonio, Massimo
• Format: Article
• Language: English
• Subjects: Depression; Depressive Disorder, Treatment-Resistant - drug therapy; esketamine; Glutamate; Humans; Ketamine - adverse effects; Mood disorders; Rapid-acting; Real-world study; treatment-resistant depression
• ISSN: 0165-0327; 1573-2517
• DOI: 10.1016/j.jad.2022.09.043

Treatment-resistant Depression (TRD) represents a widespread disorder with significant direct and indirect healthcare costs. esketamine, the S-enantiomer of ketamine, has been recently approved for TRD, but real-world studies are needed to prove its efficacy in naturalistic settings. Evaluate the effectiveness and safety of esketamine nasal spray in a clinical sample of patients with TRD from several Italian mental health services. REAL-ESK study is an observational, retrospective and multicentric study comprising a total of 116 TRD patients treated with esketamine nasal spray. Anamnestic data and psychometric assessment (MADRS, HAMD-21, HAM-A) were collected from medical records at baseline (T0), one month (T1) and three month (T2) follow-ups. A significant reduction of depressive symptoms was found at T1 and T2 compared to T0. A dramatic increase in clinical response (64.2 %) and remission rates (40.6 %) was detected at T2 compared to T1. No unexpected safety concerns were observed, side effects rates were comparable to those reported in RCTs. No differences in efficacy have been found among patients with and without psychiatric comorbidities. The open design of the study and the absence of a placebo or active comparator group are limitations. The study lacks an inter-rater reliability evaluation of the assessments among the different centres. Side effects evaluation did not involve any specific scale. Our findings support the safety and tolerability of esketamine in a real-world TRD sample. The later response and the non-inferiority in effectiveness in patients with comorbidities represent novel and interesting findings. •esketamine represent a novel agent for TRD with several RCTs proven its efficacy.•TRD subjects in real-world often include challenging cases excluded from RCTs.•REAL-ESK study comprised 116 TRD patients from several Italian real-world settings.•3-month response (64.2 %) and remission (40.6 %) were similar to RCTs reports.•Only 3/116 subjects (2.58 %) dropped out for side effects.